Passive antibody dependent cell-mediated activation
In certain embodiments, described herein is a method of treating a subject infected with a pathogen encoding an Fc-binding protein comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Also described herein is a method for treating cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Further described herein is a method of activating natural killer (NK) cells in a subject infected with a pathogen, comprising administering to the subject a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody.
1. A method of treating a subject infected with a pathogen expressing an Fc-binding protein comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to an FcγR on an immune effector cell at a first region and the pathogen-encoded Fc binding protein at a second region, wherein the first region is different than the second region, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).
2. A method for treating a cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to the pathogen-encoded Fc binding protein but does not bind to an FcγR on an immune effector cell, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).
3. The method of claim 1 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 1.
4. The method of claim 1 , wherein the FcγR is CD16a.
5. The method of claim 1 , wherein the pathogen is herpes simplex virus 1 (HSV-1).
6. The method of claim 1 , wherein the pathogen is a cytomegalovirus.
7. The method of claim 2 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 2.
8. The method of claim 2 , wherein the oncolytic viral therapy comprises administering to the subject a recombinant oncolytic herpes simplex virus (oHSV).
9. A method of activating natural killer (NK) cells in a subject infected with a pathogen, comprising administering to the subject a pharmaceutical composition consisting of an Fc fragment of a human immunoglobulin G 1 (IgG1) antibody that binds to an FcγR on an immune effector cell at a first region and the pathogen-encoded Fc binding protein at a second region, wherein the first region is different than the second region, and wherein the pathogen-encoded Fc binding protein is glycoprotein E (gE) or 68 kDa-glycoprotein (gp68).
10. The method of claim 7 , wherein the pathogen is herpes simplex virus 1 (HSV-1).
11. The method of claim 7 , wherein the pathogen is a cytomegalovirus.
12. The method of claim 7 , wherein the FcγR is CD16a.
13. The method of claim 7 , wherein the Fc fragment of the IgG1 antibody comprises SEQ ID NO: 1.